Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib
Authors
Keywords
Hepatocellular carcinoma, Sorafenib, Post-progression survival, Progression pattern
Journal
INVESTIGATIONAL NEW DRUGS
Volume 34, Issue 2, Pages 255-260
Publisher
Springer Nature
Online
2016-01-14
DOI
10.1007/s10637-016-0323-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib
- (2015) Massimo Iavarone et al. HEPATOLOGY
- Sorafenib treatment in Child–Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors
- (2015) Sadahisa Ogasawara et al. INVESTIGATIONAL NEW DRUGS
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- Prognostic Factors in Patients with Hepatocellular Carcinoma Refractory or Intolerant to Sorafenib
- (2015) Hiroyuki Okuyama et al. ONCOLOGY
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2015) et al. JOURNAL OF HEPATOLOGY
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
- (2014) Andrew X. Zhu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update
- (2014) Masatoshi Kudo et al. ONCOLOGY
- Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design
- (2013) Maria Reig et al. HEPATOLOGY
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
- (2013) Josep M. Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version
- (2011) Masatoshi Kudo et al. DIGESTIVE DISEASES
- Management of hepatocellular carcinoma: An update
- (2011) Jordi Bruix et al. HEPATOLOGY
- Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma
- (2010) Masao Omata et al. Hepatology International
- Heterogeneity in Cancer: Cancer Stem Cells versus Clonal Evolution
- (2009) Mark Shackleton et al. CELL
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search